The study reveals a novel biphasic role for nitric oxide in platelet activation, where low concentrations stimulate secretion and aggregation via NOS3 and cGMP, challenging the prevailing concept that NO is purely inhibitory.
Answers are grounded in this paper and cite their sources.
Challenges view of NO as purely inhibitory in platelets; leaves open human relevance of NOS3 in thrombosis.
Nitric oxide (NO) stimulates soluble guanylyl cyclase and, thus, enhances cyclic guanosine monophosphate (cGMP) levels. It is a currently prevailing concept that NO inhibits platelet activation. This concept, however, does not fully explain why platelet agonists stimulate NO production. Here we show that a major platelet NO synthase (NOS) isoform, NOS3, plays a stimulatory role in platelet secretion and aggregation induced by low doses of platelet agonists. Furthermore, we show that NOS3 promotes thrombosis in vivo. The stimulatory role of NOS is mediated by soluble guanylyl cyclase and results from a cGMP-dependent stimulation of platelet granule secretion. These findings delineate a novel signaling pathway in which agonists sequentially activate NOS3, elevate cGMP, and induce platelet secretion and aggregation. Our data also suggest that NO plays a biphasic role in platelet activation, a stimulatory role at low NO concentrations and an inhibitory role at high NO concentrations.
No takes yet. Share an insight, caveat, or question.
Marjanovic et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: